Differences in Whole-Blood Transcriptional Profiles in Inflammatory Bowel Disease Patients Responding to Vedolizumab Compared with Non-Responders †

Vedolizumab is efficacious in the treatment of Crohn’s disease (CD) and ulcerative colitis (UC). However, a significant proportion of patients present with a non-response. To investigate whether differences in the clinical response to vedolizumab is reflected in changes in gene expression levels in...

Descripción completa

Detalles Bibliográficos
Autores principales: Haglund, Sofie, Söderman, Jan, Almer, Sven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10052064/
https://www.ncbi.nlm.nih.gov/pubmed/36982892
http://dx.doi.org/10.3390/ijms24065820

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10052064/
https://www.ncbi.nlm.nih.gov/pubmed/36982892
http://dx.doi.org/10.3390/ijms24065820

Ejemplares similares